Dare Bioscience

Dare Bioscience R&D / Revenue

The R&D to Revenue Ratio of Dare Bioscience (DARE) as of Oct 30, 2026 is 536,147.30 %. In the previous year, R&D to Revenue Ratio was 145,188.14 % — a change of 269.28% (higher).

R&D / Revenue

536,147.30 %

YoY

269.28%

Last updated:

R&D to Revenue Ratio of Dare Bioscience is 2025 536,147.30 % . R&D to Revenue Ratio of Dare Bioscience was 2024 145,188.14 % . It decreases by 269.28% higher compared to the previous year.

The Dare Bioscience R&D / Revenue history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D / Revenue
Date
R&D / Revenue
Jan 1, 2014
14,715.00 USD
Jan 1, 2016
3,598.56 USD
Jan 1, 2021
306.18 USD
Jan 1, 2022
300.42 USD
Jan 1, 2023
767.06 USD
Jan 1, 2024
145,188.14 USD
Jan 1, 2025
536,147.30 USD
The Dare Bioscience R&D / Revenue history
YEARR&D / RevenueYoY
536,147.30 %+269.28%
145,188.14 %+18,827.95%
767.06 %+155.33%
300.42 %-1.88%
306.18 %-91.49%
3,598.56 %-75.54%
14,715.00 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Dare Bioscience Stock analysis

What does Dare Bioscience do? Daré Bioscience, Inc. develops and commercializes pharmaceutical products in women's reproductive health, focusing on non-hormonal contraceptive solutions. Its lead product, Ovaprene, is a clinical stage intravaginal ring designed to provide multi-week protection without intervention during intercourse. The ring features a permeable mesh barrier and localized spermiostatic agent delivery, combining barrier and spermicidal mechanisms to achieve efficacy comparable to diaphragms and short-acting hormonal methods like oral pills and vaginal rings. The company targets women seeking non-hormonal contraceptive options, with Ovaprene positioned as an alternative to existing hormonal products and barrier methods. The firm generates revenue through the development and commercialization of Ovaprene, aiming to address unmet needs in women's reproductive health. Ovaprene is designed to offer a non-hormonal, user-friendly alternative to traditional hormonal contraceptives, appealing to consumers who prefer avoiding hormonal side effects. The company's focus on clinical development and product commercialization aligns with the market demand for innovative, non-hormonal contraceptive options in women's health. Dare Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Dare Bioscience stock

R&D to Revenue Ratio of Dare Bioscience is 536,147.30 % in 2025.

R&D to Revenue Ratio of Dare Bioscience changed from 145,188.14 % to 536,147.30 %, representing a 269.28% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of R&D to Revenue Ratio Dare Bioscience since 2006 – with annual values, charts, and detailed analysis.

The R&D to Revenue ratio shows what percentage of revenue a company invests in research and development. Higher ratios indicate stronger focus on innovation.

A 'good' varies by industry and company stage. On Eulerpool, you can compare R&D to Revenue Ratio's Dare Bioscience with sector peers and the industry average to assess whether it is attractive.

To evaluate R&D to Revenue Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for R&D to Revenue Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Dare Bioscience

All Key Metrics — Dare Bioscience